425: Runway Growth Finance Q3 2025: SWK Merger & NII Growth

Runway Growth Finance reported increased net investment income for Q3 2025 and provided updates on its strategic acquisition of SWK Holdings, now expected to close in early 2026.

Summary

• Total investment income reached $36.7 million, with net investment income (NII) at $15.7 million for Q3 2025, an increase from Q2 2025.
• Funded $128.3 million across 11 investments in new and existing portfolio companies, focusing on technology, healthcare, and select consumer sectors.
• Announced a definitive merger agreement to acquire SWK Holdings, a specialty finance company, expected to scale the portfolio by an estimated $242 million and increase healthcare/life sciences exposure from 14% to approximately 31%.
• The SWK merger is anticipated to generate mid-single digit run-rate NII accretion in the first full quarter post-close and support modest ROE expansion and improved dividend coverage.
• NAV per share decreased to $13.55 from $13.66 in Q2 2025, and the weighted average portfolio risk rating increased to 2.42 from 2.33.
• The external investment adviser is contributing $9 million in cash to the SWK transaction, equivalent to nearly three full quarters of fee waiver.
• The merger closing is now anticipated in early 2026 due to expected delays in SEC regulatory approval caused by the government shutdown.

Sentiment

Score: 6

Explanation: The filing presents a mixed financial picture with increased NII but decreased NAV and increased portfolio risk. However, the strategic acquisition of SWK Holdings is a significant positive, promising future growth, diversification, and NII accretion, supported by a substantial adviser contribution. The delay in merger close and some negative financial trends temper overall enthusiasm.

Positives

• Net investment income increased to $15.7 million in Q3 2025 from $13.9 million in Q2 2025.
• Total investment income increased to $36.7 million in Q3 2025 from $35.1 million in Q2 2025.
• NII per share of $0.43 covered the base dividend of $0.33 per share.
• Dollar-weighted average annualized yield increased to 16.8% in Q3 2025 from 15.4% in Q2 2025 and 15.9% for the comparable period last year.
• Total operating expenses decreased to $21.0 million in Q3 2025 from $21.2 million in Q2 2025.
• Net realized loss on investments decreased to $1.3 million in Q3 2025 from $1.5 million in Q2 2025.
• Leverage ratio decreased to 0.92 from 1.05 in Q2 2025, and asset coverage increased to 2.09 times from 1.95 times.
• Strategic acquisition of SWK Holdings is expected to immediately scale the portfolio by an estimated $242 million and enhance earnings power, ROE, and dividend coverage.
• The SWK acquisition will expand exposure to the defensive healthcare and life sciences sector from 14% to approximately 31% of the portfolio.
• The external investment adviser is contributing $9 million in cash to the SWK transaction, equivalent to a significant fee waiver.
• The adviser agreed to maintain the base management fee at 1.50% despite total assets suggesting a 1.60% fee.
• Repurchased 397,983 shares under the $25 million stock repurchase program.
• The portfolio is 97% floating-rate assets and almost exclusively first lien senior secured loans, reflecting a focus on risk mitigation.

Negatives

• NAV per share decreased to $13.55 in Q3 2025 from $13.66 in Q2 2025, a 1.9% decline.
• Total investment portfolio fair value decreased by 7.7% to $946 million from $1.02 billion in Q2 2025.
• Weighted average portfolio risk rating increased to 2.42 in Q3 2025 from 2.33 in Q2 2025 (scale of 1 to 5, 1 being most favorable, indicating increased risk).
• Dollar-weighted loan-to-value ratio increased to 31.4% from 29.6%.
• One loan, Mingle Healthcare, is on non-accrual status with a fair market value of $2.4 million, 50% of its $4.8 million cost basis.
• The use of the share repurchase program was limited during the quarter due to a blackout period associated with the SWK transaction.

Risks

• Uncertainties associated with market conditions caused by interest rates and changing economic conditions.
• The ability of the parties to consummate the SWK merger on the expected timeline, or at all.
• The realization of expected synergies, savings, and anticipated benefits from the merger.
• The impact of the merger on the depth of trading in Runway's common stock post-closing.
• Risks related to diverting management's attention from ongoing business operations due to the merger.
• The possibility that any or all conditions to the merger may not be satisfied or waived.
• The future operating results and net investment income projections of the combined company may differ from expectations.
• The ability of Runway Growth Capital LLC and its affiliates to attract and retain highly talented professionals.
• The expected financings and investments and additional leverage that the combined company may seek to incur in the future.
• The adequacy of the cash resources and working capital of the combined company.
• Stockholder litigation in connection with the merger may result in significant costs of defense and liability.

Future Outlook

Management anticipates the SWK Holdings merger will close in early 2026, generating mid-single digit run-rate net investment income accretion in the first full quarter post-close, supporting modest ROE expansion and improved dividend coverage. The transaction is expected to offset recent repayment impacts, preserve earnings power, and maintain the dividend. Origination activity in Q4 is expected to utilize the BC Partners Credit platform, while repayment activity is projected to be relatively muted compared to Q3. The company expects a normal course of prepayments going forward. The dividend decision for Q4 was made with an anticipation of heavy prepayments and potential interest rate decreases, with Q4 earnings expected to cover the base dividend.

Management Comments

• "Despite a challenging deal environment and significant changes to the venture ecosystem, we have always been proactive in positioning the platform to compete with the best in the business." David Spreng, CEO
• "We believe our third quarter investment activity is only beginning to show the benefits of our integration within the BC Partners Credit ecosystem." David Spreng, CEO
• "We think this deal makes both strategic and financial sense for Runway." David Spreng, CEO
• "This transaction expands our commitment to the healthcare and life sciences industries, which we believe is defensive by nature of high barriers to entry given the time and investment needed for FDA approvals, as well as limited downside risk and excellent risk adjusted returns." Greg Greifeld, CIO
• "We believe this deal demonstrates our ability to structure, win, and complete transactions, utilizing both cash and equity, to drive scale and enhance our market position." Greg Greifeld, CIO
• "Earnings for the quarter benefited from elevated prepayment income." Thomas Raterman, CFO and COO
• "We anticipate this transaction will generate mid-single digit run-rate net investment income accretion during the first full quarter following the close and support modest ROE expansion, as well as improved dividend coverage." Thomas Raterman, CFO and COO
• "This significant contribution from the adviser equates to a fee waiver of nearly three full quarters, when calculated on a pre-tax basis." Thomas Raterman, CFO and COO
• "Taking into consideration the ongoing Government shutdown, we expect delays in the SEC regulatory approval process and anticipate the close to take place in early 2026." Thomas Raterman, CFO and COO

Industry Context

The company operates in a challenging deal environment with increasing competition across private markets and significant changes in the venture ecosystem. The strategic acquisition of SWK Holdings aligns with a broader trend of BDC consolidation, where BC Partners Credit has been an active player. While venture debt has seen some spread compression, it has been less severe than in the broader middle market. The company aims to solidify its standing as a serious participant in the consolidating venture and growth lending markets, adapting to shifting rates and a changing venture debt landscape.

Comparison to Industry Standards

• The company aims to "compete with the best in the business" and believes its inorganic growth strategy "sets us apart from our peers" due to the BC Partners Credit platform's experience in BDC consolidation.
• The healthcare and life sciences sector is highlighted as defensive due to "high barriers to entry given the time and investment needed for FDA approvals, as well as limited downside risk and excellent risk adjusted returns," implying a favorable comparison to other sectors.
• No specific comparable companies, projects, or global benchmarks were explicitly detailed in the filing for direct comparison of results.

Legal Proceedings

• Stockholder litigation in connection with the merger may result in significant costs of defense and liability.

Related Party Transactions

• The external investment adviser is contributing $9 million in cash as part of the consideration for the SWK merger.
• An equity investment of $6.7 million was made to Runway-Cadma I, a joint venture with Cadma Capital Partners.

Stakeholder Impact

• Shareholders: Expected enhanced earnings power, modest ROE expansion, improved dividend coverage, and increased trading liquidity post-merger. Oaktree's percentage ownership position will be reduced.
• Borrowers: Expanded suite of financing solutions and Runway aims to be a "destination of choice for growth investment."
• Employees (SWK team): SWK team will join Runway for transition services, assisting with portfolio, relationships, and new originations.

Next Steps

• SEC regulatory approval process for the SWK merger.
• Closing of the SWK Holdings merger, anticipated in early 2026.
• Integration of the SWK team and portfolio onto Runway's platform.
• Re-exploring opportunities to upsize the best loans in the SWK portfolio for organic growth.
• Continued evaluation of all opportunities that align with a disciplined approach to inorganic growth.
• Rebuilding the portfolio in Q4 to cover the base dividend.
• Continued assessment of the portfolio and venture landscape to deliver attractive risk-adjusted returns.
• Making continued strides on objectives outlined upon joining the BC Partners Credit platform.
• Discussing Q4 2025 financial results in the new year.

Key Dates

Recommendation

The strategic acquisition of SWK Holdings is a significant long-term positive, promising portfolio scale, diversification into a defensive sector, and future earnings accretion, further bolstered by the adviser's substantial cash contribution. However, the recent quarter showed a decline in NAV per share, an increase in portfolio risk rating, and a decrease in total investment portfolio fair value. While NII covered the dividend, management indicated it benefited from elevated prepayments and the dividend decision was forward-looking. The delay in the merger close adds a minor uncertainty. Given the mixed current financial performance against a strong strategic move, a 'hold' recommendation is appropriate, awaiting clearer execution on the merger and stabilization of core portfolio metrics.

Keywords

Venture Debt, BDC, SEC Filing, Merger, SWK Holdings, Healthcare Finance, Life Sciences, Financial Results, Q3 2025, Net Investment Income, NAV, Portfolio Diversification, BC Partners Credit, Growth Lending, Acquisition